Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
55 hedge funds and large institutions have $308M invested in Bellicum Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 55 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$91.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$32.4M |
| 3 |
PA
Perceptive Advisors
New York
|
+$22.4M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$22M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$18.5M |
Top Sellers
BLCM Hedge Fund Activity: Q4 2014 in Review
55 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2014, worth a combined $308M.
Buyers outnumbered sellers: 55 funds opened new BLCM positions and 0 closed out — a net gain of 55 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $91.9M.
- 55 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $308M of Bellicum Pharmaceuticals, Inc. stock for Q4 2014.
- 55 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2014 and 0 closed out, a net change of +55 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2014 was Baker Bros. Advisors, an estimated $91.9M added.
Based on aggregated 13F filings for Q4 2014.